Geraldine Harriman
Tracked across 1 events · 6 articles · First seen May 20, 2026 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Geraldine Harriman, Co-Founder and Chief Scientific Officer of Knight Therapeutics, provided commentary on the significance of the IRF5 program and its potential impact on autoimmune diseases.
May 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Geraldine Harriman live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard